Purinone antianginal agents
US5734053A · kind A · utility
27Cited by
2References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 4, 1996 |
| Grant date | Mar 31, 1998 |
| Priority date | — |
| Expiry date | Oct 4, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D473/30
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
##STR1## Compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R.sup.1 is C.sub.1 -C.sub.4 alkyl; R.sup.2 is C.sub.2 -C.sub.4 alkyl; R.sup.3 is H or SO.sub.2 NR.sup.4 R.sup.5 ; R.sup.4 and R.sup.5 together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino or 4-N-(R.sup.6)-1-piperazinyl group; and R.sup.6 is H or C.sub.1 -C.sub.3 alkyl; are selective cGMP PDE inhibitors useful in the treatment of, inter alia, cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.